Get the Stockscreener App
1.53
12.57%
-0.22
Pre-market:
1.52
-0.01
-0.65%
Cvrx Inc stock is traded at $1.53, with a volume of 1.45M.
It is down -12.57% in the last 24 hours and down -49.67% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$1.75
Open:
$1.745
24h Volume:
1.45M
Relative Volume:
1.69
Market Cap:
$40.76M
Revenue:
$59.07M
Net Income/Loss:
$-52.66M
P/E Ratio:
-0.7612
EPS:
-2.01
Net Cash Flow:
$-40.16M
1W Performance:
-39.53%
1M Performance:
-49.67%
6M Performance:
-83.19%
1Y Performance:
-80.78%
1-Day Range:
$1.50
$1.79
1-Week Range:
$1.50
$2.79
52-Week Range:
$1.50
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
1.53 | 71.93M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
96.69 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.44 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.96 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.23 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.19 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
$CVRX stock is down 33% today. Here's what we see in our data. - Quiver Quantitative
Why Is CVRx (NASDAQ:CVRX) Suddenly a Must-Watch Smallcap Stocks Name? - kalkinemedia.com
CVRx, Inc. Announces Late-Breaking Data And New Clinical Evidence On Barostim At The HFSA Annual Scientific Meeting 2026 - marketscreener.com
CVRX Oct 2026 2.500 call (CVRX261016C00002500) Stock Historical Prices & DataYahoo Finance - Yahoo! Finance Canada
CVRX Oct 2026 10.000 call (CVRX261016C00010000) stock historical prices and data - uk.finance.yahoo.com
CVRX Oct 2026 5.000 put (CVRX261016P00005000) Stock Price, News, Quote & History - Yahoo! Finance Canada
CVRX Oct 2026 10.000 call (CVRX261016C00010000) interactive stock chart - uk.finance.yahoo.com
CVRx stock falls 6.99 percent as CFO transition takes shape - AD HOC NEWS
CVRX Oct 2026 2.500 put (CVRX261016P00002500) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
CVRX Oct 2026 2.500 call (CVRX261016C00002500) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages - GlobeNewswire
CVRx names John Landry as CFO - MedTech Dive
CVRx Inc. (CVRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CVRx taps new CFO from Nyxoah - MassDevice
CVRx, Inc. (CVRX) stock price, news, quote and history - Yahoo Finance UK
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Hold Rating - Moomoo
Lake Street Downgrades CVRx Inc(CVRX.US) to Hold Rating, Cuts Target Price to $3.5 - Moomoo
Canaccord reiterates CVRx stock Buy rating after CFO appointment By Investing.com - Investing.com South Africa
Canaccord reiterates CVRx stock Buy rating after CFO appointment - Investing.com
CVRx Faces Fresh Pressure as Activist Pushes a Sale - finimize.com
CVRx appoints John Landry as chief financial officer By Investing.com - Investing.com South Africa
CVRx Appoints John Landry as Chief Financial Officer - Minichart
CVRX Q2 2026 Earnings: Narrower-Than-Expected Loss Met With a 2.3% PullbackEarnings Quality Analysis - siam.in
CVRx appoints John Landry as chief financial officer - Investing.com
CVRx Names New Chief Financial Officer - marketscreener.com
Cvrx Appoints John Landry As Chief Financial Officer - TradingView
CVRx, Inc. Appoints John Landry as Chief Financial Officer, Effective October 12, 2026 - marketscreener.com
CVRx stock holds steady as investors eye latest revenue growth - AD HOC NEWS
CVRx stock dips as Cantor slashes price target after guidance update - AD HOC NEWS
Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing. - Pluang
CVRX Q2 2026 Earnings: Narrower-Than-Expected Loss, But Shares Slip 1.38%Earnings Outlook Update - dars.gov.et
CVRX stock edges higher as investors watch neuromodulation growth - ad-hoc-news.de
CVRX stock benefits as Barostim heart failure therapy gains new Medicare Advantage coverage - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx Secures Devoted Health Coverage for Barostim Therapy - Prime Publishers, Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Shareholders to Connect - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - accessnewswire.com
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - qz.com
CVRx has an activist investor urging it to get acquired - MassDevice
CVRx Responds to Letter from Pointillist Family Office - marketscreener.com
3 Penny Stocks With At Least $70M Market Cap - Simply Wall Street
CVRx earns new Medicare Advantage coverage policy for Barostim - MassDevice
CVRx Inc. Faces Securities Law Investigation Over Revenue Guidance Cut and DOJ Demand - kalkine.ca
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Nigeria
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - The Manila Times
Jorey Chernett, Owner of More Than 5.5% of Ou - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Binkowski Brent | CHIEF OPERATING OFFICER |
Aug 12 '26 |
Sale |
2.55 |
1,309 |
3,338 |
30,291 |
| Adamson Philip B. | Chief Medical Officer |
Mar 02 '26 |
Sale |
7.90 |
1,262 |
9,973 |
61,578 |
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):